Press release -
Immedica welcomes Linda Holmström as Head of Communication
It is with great pleasure we today welcome Linda Holmström, who is an experienced stock exchange- and corporate brand communicator. Linda will take the role as Head of Communication and be responsible for both our external corporate branding including ESG and sustainability communication as well as being tightly involved in our European launches, with focus on our digital platforms and interfaces.
Linda brings extensive experience from roles within Communications and Investor Relations in Pharma and Biotech companies, mainly listed on the Stockholm Stock Exchange. Prior to joining Immedica Linda held the position as Director of Investor Relations at Oncopeptides, and before that she held senior Communications and Investor Relations positions at Sobi and Recipharm. At Recipharm she was strongly involved in the execution of the successful IPO. Linda will join the extended Leadership Team.
Linda holds a Master of Science degree in Chemical Engineering from the Royal Institute of Technology, Stockholm as well as a Diploma in Marketing and Communications from IHM Business School.
Topics
- Diseases
Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East.
Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality and product distribution.
